Screening of Coexistence Between Sickle Cell Anaemia and G6PD Deficiency

NCT ID: NCT06615024

Last Updated: 2024-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-31

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

G6PD deficiency may have a subtle effect on the severity of hemolysis and also worsen the degree of anaemia in SCD when the two disorders coexist. Therefore, selective decision should be taken in patients in whom the two conditions coexist in the choice of drug and in the treatment of infections.The prevalence of the G-6-PD deficiency is high in SCD patients, but does not differ from that observed among non-SCD subjects .However, the G-6-PD deficiency appears to worsen the clinical features of SCD, there were more hospitalizations, major vaso-occlusive crises among G-6-PD deficient sickle cell patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sickle cell disease (SCD) is not frequent in Egypt except in the Oases where the carrier rate varies from 9 to 22%. It is a hereditary blood disorder characterized by the production of abnormal hemoglobin molecules that cause red blood cells to take on a crescent or sickle shape. This haemoglobin called haemoglobin S, which causes red blood cells to become stiff and sticky, leading to various health complications as recurrent pain, fatigue, anaemia, and increased infection susceptibility.prevalence of G6PD deficiency is 4.3% with a male:female ratio of 3.2:1. Enzyme activity was significantly higher in males than females. It is located on X chromosome which leads to a lower level of reduced glutathione, an antioxidant, in red blood cells (RBCs). Most of the time, those who are affected have no symptoms. However, they should avoid specific triggers that may promote oxidative stress such as fava beans, that may fragilize RBCs and cause hemolysis. G6PD deficiency may have a subtle effect on the severity of hemolysis and also worsen the degree of anaemia in SCD when the two disorders coexist. Therefore, selective decision should be taken in patients in whom the two conditions coexist in the choice of drug and in the treatment of infections. The prevalence of the G-6-PD deficiency is high in SCD patients, but does not differ from that observed among non-SCD subjects .However, the G-6-PD deficiency appears to worsen the clinical features of SCD, there were more hospitalizations, major vaso-occlusive crises among G-6-PD deficient sickle cell patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease and G6PD Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Newborns who are delivered in NEW VALLEY GOVERNORATE

Screening of coexistence between sickle cell anaemia and G6PD deficiency

G6pd enzyme sickling test

Intervention Type DIAGNOSTIC_TEST

Measuring the enzyme level of G6PD and presence of Hbs

G6PD enzyme and sickling test

Intervention Type DIAGNOSTIC_TEST

Measuring enzyme level of G6PD and level of HbS

G6PD enzyme and HPLC

Intervention Type DIAGNOSTIC_TEST

Measuring G6PD enzyme level in neonates and measuring level of HbS

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

G6pd enzyme sickling test

Measuring the enzyme level of G6PD and presence of Hbs

Intervention Type DIAGNOSTIC_TEST

G6PD enzyme and sickling test

Measuring enzyme level of G6PD and level of HbS

Intervention Type DIAGNOSTIC_TEST

G6PD enzyme and HPLC

Measuring G6PD enzyme level in neonates and measuring level of HbS

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- All new born with good general health

Exclusion Criteria

* 1-new born with high reticulocytic count 2-new born with bad general health
Minimum Eligible Age

1 Day

Maximum Eligible Age

28 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fatma Hussein Mahmoud

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Fatma Hussein Mahmoud

Assistant lecturer

Responsibility Role SPONSOR_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fatma Hussein Mahmoud, Assistant lecturer

Role: CONTACT

01062172982 ext. +2

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Coexistence of SCD and G6PD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.